Clinical and biological features of cerebral venous sinus thrombosis following ChAdOx1 nCov-19 vaccination

Cerebral vein thrombosis after ChAdOx1 nCov‐19 vaccination: Long‐term outcome of four patients

“…Target activated partial thromboplastin time ratio was 1.5–2.0 for the first 48 h, increased to 2.0–2.5 in the absence of further bleeding or deterioration on repeat imaging in those with subarachnoid hemorrhage. There was no progression of ICH with argatroban, and platelet count gradually improved following the start of IV IgG and high‐dose steroids 5 (Figure 1A–D ). A single dose of rituximab (375 mg/m 2 ) was given to two patients (Figure 1A,B ).…”

“…When serum from patients with VITT was incubated with low‐ or high‐dose UFH, there was a variable response in platelet aggregation. 5 All four patients received a uniform management approach with immediate transfer to an intensive care unit with combined hyperacute stroke unit and neurosurgical presence on initial presentation. Urgent plasma exchange (PLEX) with Octaplas was initiated within 24 h and continued for 5 days.…”